ODA at ASCO 2022

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Ash Alpert. Thank you so much for joining us. Ash Alpert, MD, MFA: I'm Dr. Ash Alpert. I'm a postdoctoral fellow in health services research at Brown University, and I'm a hematologist and medical oncologist. My research focuses on improving the experiences and outcomes of transgender people with cancer. Oncology Data Advisor: Would you like to tell us a little bit about the two posters that you presented at ASCO re...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Colin Ferro from Epic Experience. Thank you so much for joining us. Mr. Ferro: Thank you for having me.  Our mission is to empower adult cancer survivors and thrivers beyond their cancer diagnosis." by Author Oncology Data Advisor: Would you like to tell us a little bit about Epic Experience and what you do? Mr. Ferro: So, Epic Experience is a nonpro...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Ian Krop of Yale University who presented data on the novel HER3-targeting antibody-drug conjugate patritumab deruxtecan in HER3-expressing metastatic breast cancer. Thank you for joining us, Dr. Krop. Ian Krop, MD, PhD: I'm happy to be here. And just so you know, we all call it just HER3-DXd, which is a lot easier to say than patritumab deruxtecan. Oncology Data Advisor: Thank you. Why is there so much excitement about ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Jeannie Tie from the Peter MacCallum Cancer Centre at the University of Melbourne and Walter and Eliza Hall Institute. She presented the results of the randomized DYNAMIC trial on adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer. This work was also just published in the New England Journal of Medicine. Thank you for joining us, Dr. Tie. Jeanne Tie, MD, MBChB, FRACP: You're welcome. ...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here at the ASCO Annual Meeting in Chicago speaking with Jessica Jones of the UT Health System. Thank you so much for joining us here. Jessica Jones, MD: Thank you for having me. Oncology Data Advisor: Yes, absolutely. So you've done a lot of work and research in breast cancer prevention, especially for Black American women. Would you like to tell us about that? Dr. Jones: Yes. Thank you for asking. So I'd like t...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm here with Dr. Alexander Spira, Director of the Thoracic and Phase I Program for the Virginia Cancer Specialists, the US Oncology Network. He just presented his research as part of the oral abstract session on non–small cell lung cancer at the ASCO 2022 Annual Meeting, and it is also being published in today's New England Journal of Medicine. Dr. Spira, would you like to comment on the significance of these results of adagrasib for KRAS...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago speaking with Jason Mouabbi from MD Anderson Cancer Center. Thank you so much for joining us today. Jason Mouabbi, MD: Thank you, happy to be here. Oncology Data Advisor: Would you like to tell us a little bit about your poster here? Dr. Mouabbi: Yes, sure. At MD Anderson, I'm responsible for lobular breast cancer. I'm an expert in that field. Recently, we have shown in...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I am Lyn Brook. Today I am joined by Cherry Au, Resident Physician at Rush University Medical Center. Recently at ASCO, she presented her abstract about medical student readiness for treating sexual and gender minority patients with confidence and comfortability. Would you like to begin with introducing yourself and telling us a bit about your interests and what you study? Cherry Au, MD: Yeah. My name is Cherry Au. I'm currently a Postgrad...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Megan-Claire Chase of SHARE Cancer Support. Megan-Claire, thank you so much for being with us today. Megan-Claire Chase: Thank you so much. I'm so excited. Oncology Data Advisor: So, would you like to tell us a little bit about your story? Ms. Chase: Yes. So, my story begins like this; I always knew I would get cancer, and that's not because I'm a pessimi...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Urvi Shah from Memorial Sloan Kettering Cancer Center (MSKCC). Thank you for joining us. Would you like to tell us a little bit about yourself? Urvi Shah, MD: Sure. I'm a Hematologist and Oncologist on the Myeloma Service at Memorial Sloan Kettering Cancer Center. I'm happy to be here to talk to you all. Oncology Data: I know you moderated the poster disc...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Beth Heller and I'm at the ASCO 2022 Annual Meeting with Dr. Gombos. How are you today? And what are you doing at ASCO? Dan Gombos, MD, FACS: I'm doing great. ASCO is really the preeminent meeting for people who practice medical oncology. My world is a little bit different because I'm an ocular oncologist. Oncology Data Advisor: You are the first ocular oncologist I've ever met. Dr. Gombos: Well, ocular oncology is a very small, subspe...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, and I'm speaking with Kathi Mooney from Huntsman Cancer Institute. Thank you so much for joining us. Would you like to tell us a little bit about what you do? Kathi Mooney, PhD, RN, FAAN: Yes. Thank you for having me. I am Kathi Mooney, and I am from the University of Utah where the Huntsman Cancer Institute is, and I am here presenting two pieces of our research that ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Mark T. Fleming, a Medical Oncologist from the Virginia Oncology Associates, the US Oncology Network, who is at the ASCO 2022 Annual Meeting to present his work on the impact of diversity, equity, and inclusion training in an independent community oncology practice. Thank you for joining us, Dr. Fleming. Mark Fleming, MD: Thank you for having me. Oncology Data Advisor: Thanks. What is the importance of including diversity, e...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here at the ASCO Annual Meeting in Chicago speaking with Leif Honda and Jon Wetzel from TriMetis Life Sciences. Thank you for joining us here. Leif Honda: Thank you, Keira. It's good to be here. Oncology Data Advisor: Would you like to introduce yourselves? Jon Wetzel: Hi, I'm Jon Wetzel and I'm the COO here of TriMetis. We want to use those tools to help us when we're talking about the development of therapeutic...
Navdeep Dehar, MD, MBT, CCRP: My name is Navdeep Dehar and I am from Queen's University. I am a Medical Oncology Fellow there, and I am here to learn. This is my first ASCO. Oncology Data Advisor: Awesome. So, what are some of the most exciting things that you've seen here at ASCO so far? It's always important to see the person who you are giving the treatments to, not the disease you are treating by Author Dr. Dehar: I have attended the Presidential Address, which was exciting. I also heard dif...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Dr. Sam Kareff from the University of Miami. Thank you so much for joining us today. Sam Kareff, MD, MPH: Thanks for having me. Oncology Data Advisor: So, would you like to tell us about your poster that you presented here? Dr. Kareff: Sure. So, for our group, in conjunction at the University of Miami and the Caris Precision Oncology Alliance, I presented...
Oncology Data Advisor: Would you like to introduce and tell us a bit about yourself? Nick Dionne-Odom, PhD, RN: My name is Nick Dionne-Odom. I'm an Assistant Professor in the School of Nursing at the University of Alabama at Birmingham. Oncology Data Advisor: Would you like to give us an overview of the bias experienced by caregivers regarding cancer-related decisions? Dr. Dionne-Odom: Sure. I partnered with a 401(c)3 called Cancer Care, which is based in New York, to conduct a large national su...
Oncology Data Advisor™ · Medical Student Readiness to Treat LGBTQIA+ Patients: Matthew Schabath, PhD At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Matt Schabath, Associate Researcher at Moffitt Cancer Center, met with Oncology Data Advisor to discuss medical student readiness and confidence when treating LGBTQIA+ patients. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. Oncolog...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Danet Peterson. Danet, thank you for joining us. Would you like to tell us a little bit about yourself? Danet Peterson: Sure. I am here from Phoenix, Arizona, and I'm here with the organization A Cure in Sight. We are a nonprofit for patients, created by patients, with ocular melanoma. I was actually diagnosed with ocular melanoma myself in July of 2020. ...
Oncology Data Advisor: Would you like to introduce yourself and give us an overview of your presentations this year at ASCO? Debra Patt, MD, PhD, MBA, FASCO: My name is Dr. Debra Patt. I serve as an Executive Vice President of Texas Oncology, part of the US Oncology Network. And I'm excited, at ASCO, to present information on our digital health solutions. One of the first studies that we presented looks at characteristics of utilization among different patient populations with our digital health...
Oncology Data Advisor: Hello, I'm Beth Heller, and I'm here today with Oncology Data Advisor at ASCO 2022. Stephanie Van Winkle: I'm Stephanie Van Winkle, and I'm Executive Director of Oncology State Societies at the Association for Community Cancer Centers. Oncology Data Advisor: What are you doing here at ASCO? Stephanie Van Winkle: My organization manages 21 of the state oncology societies across the country, and we are part of the state affiliate program of ASCO. So if you walk into the exhi...
Oncology Data Advisor™ · The Nurse's Role in Oncology Research and Quality Care: Jeannine Brant, PhD, APRN At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Jeannine Brant, PhD, APRN, President of the Oncology Nursing Society (ONS), sat down with Oncology Data Advisor to talk about the exciting research being presented by nurses at ASCO and the critical role of nurses in delivering quality oncology care. This podcast episode was recorded live at t...
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Beth Koselke, PharmD, BCOP, of the US Oncology Network, presented her team's research regarding the impact of a clinical pharmacist intervention program in oncology trial enrollment. Afterwards, she spoke with Oncology Data Advisor to explain the significance of the study's results and to further enlighten us about the role that pharmacists can play in clinical trial design, screening, and enrollment. Oncology ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Beth Peck from Project Koru. Thank you so much for joining us here. Beth Peck: Thanks for having me. Oncology Data Advisor: Tell us about Project Koru. What do you do? Ms. Peck: Project Koru is really in the realm of survivorship. We serve young adult cancer survivors who are between the ages 19 to 39, once they're done with their treatment and they've go...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here at the ASCO Annual Meeting in Chicago, speaking with David Penberthy of the Association of Community Cancer Centers. Thank you for joining us. Would you like to tell us a little bit about what you do there? David Penberthy, MD, MBA: Sure, thank you for having me. I'm really excited to be here at ASCO 2022. My name is David Penberthy. I'm a radiation oncologist in practice in the southern part of Virginia. I'...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today I'm at the ASCO Annual Meeting in Chicago, speaking with Dr. Aamir Ehsan, who is President of CorePath Laboratories. Thank you for joining us. Aamir Ehsan, MD: You're welcome. Oncology Data Advisor: So, would you like to tell us a little bit about personalized and precise diagnosis of cancer by pathology? Dr. Ehsan: Yes, sure. Thank you for the opportunity. My name, as you said, is Aamir Ehsan, representing a Clinica...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Deb Lundquist, Clinical Research Nurse from Massachusetts General Hospital. Recently, she provided a presentation at the 2022 ASCO Annual Meeting titled Patient-Reported Hope, Quality of Life, Symptom Burden, and Coping Mechanisms in Early Phase Clinical Trial Participants. Would you like to introduce yourself, what you do, and some things you are interested in? Debra Lundquist, PhD, RN: Sure. My name is Deb Lundqui...
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Melissa Hudson of St. Jude Research Hospital, spoke with Oncology Data Advisor about the phase II trial of dabrafenib/trametinib for BRAF V600–mutant pediatric low-grade glioma, which was presented at the meeting by Dr. Eric Bouffet of the University of Toronto's Hospital for Sick Children. Dr. Hudson provides commentary on the study's results and shares additional insights into her research regar...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Ash Alpert. Thank you so much for joining us. Ash Alpert, MD, MFA: I'm Dr. Ash Alpert. I'm a postdoctoral fellow in health services research at Brown University, and I'm a hematologist and medical oncologist. My research focuses on improving the experiences and outcomes of transgender people with cancer. Oncology Data Advisor: Would you like to tell us a little bit about the two posters that you presented at ASCO re...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Deb Lundquist, Clinical Research Nurse from Massachusetts General Hospital. Recently, she provided a presentation at the 2022 ASCO Annual Meeting titled Patient-Reported Hope, Quality of Life, Symptom Burden, and Coping Mechanisms in Early Phase Clinical Trial Participants. Would you like to introduce yourself, what you do, and some things you are interested in? Debra Lundquist, PhD, RN: Sure. My name is Deb Lundqui...

Copyright © 2022 Oncology Data Advisor. All rights reserved.